In This Story
MoonLake Immunotherapeutics (MLTX-3.85%) has submitted its 10-Q filing for the quarterly period ended September 30, 2024.
The filing includes financial statements for the quarter, showing research and development expenses of $35,735,514, an increase from $7,585,136 in the same quarter the previous year. This increase is attributed to higher costs associated with clinical development trials and supply services.
General and administrative expenses were reported at $7,376,495, up from $5,391,607 in the previous year, primarily due to increased personnel-related costs.
Other income, net, was $7,089,691 for the quarter, compared to $1,386,313 in the previous year, largely due to increased realized interest on cash and investments.
The company reported a net loss of $36,114,424 for the quarter, compared to $11,619,353 in the previous year.
MoonLake had cash and cash equivalents of $375,656,291 as of September 30, 2024. The company believes it has sufficient capital to fund operations until the end of 2026.
The filing details MoonLake's ongoing development of Sonelokimab (SLK), a tri-specific Nanobody aimed at treating inflammatory skin and joint diseases. The company is advancing SLK through various clinical trials, including Phase 3 trials for hidradenitis suppurativa and psoriatic arthritis.
MoonLake continues to focus on expanding its clinical and commercial capabilities, including building out its manufacturing and commercialization infrastructure to support potential future product launches.
The company did not generate any revenue from product sales during the quarter and expects to continue incurring significant expenses as it advances its clinical programs.
MoonLake's financial strategy includes potential additional funding through equity, debt offerings, or strategic partnerships to support its operations and development plans.
This content was summarized by generative artificial intelligence using public filings retrieved from SEC.gov. The original data was derived from the MoonLake Immunotherapeutics quarterly 10-Q report dated November 7, 2024. To report an error, please email earnings@qz.com.